跳至主要内容
临床试验/NCT04670172
NCT04670172招募中不适用

Real-Life Chronic Rhinosinusitis Outcome Registry

Change Accelerator in Respiratory Care13 个研究点 分布在 10 个国家目标入组 4,550 人开始时间: 2021年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
4,550
试验地点
13
主要终点
Symptom severity total symptoms

研究概览

简要总结

An international consortium of leading medical experts in the field of chronic respiratory disease, the research team of Galenus Health and the non-profit organization EUFOREA (European Forum for Research and Education in Allergy and Airway diseases) has been conceived to conduct real-life outcome research. The Galenus Health digital platform consisting of a mobile application for patients and an online dashboard for physicians will be implemented in each of the participating centres. The data will be centralized in a pseudonymized database and will be the basis of the Chronic RhinoSinusitis Outcome Registry.

详细描述

This real-life chronic rhinosinusitis outcome registry aims at longitudinal data collection from patients attending specialist care centres across Europe.

As primary aim it intends to provide new insights on the burden of uncontrolled disease, the impact on health-related quality of life, productivity loss as well as the effect of disease severity and co-morbid disease on these outcome parameters.

In addition this outcome registry intends to identify patients eligible for type 2 targeted biologic therapy, evaluate treatment effectiveness and markers of treatment response.

Beyond that direct and indirect costs for society related to chronic rhinosinusitis and its' treatment will be studied.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Physician diagnosis of Chronic RhinoSinusitis
  • Capable of using a mobile application on a smartphone

排除标准

  • Patients with malignancies of the sinonasal cavity
  • Patients with inverted papilloma
  • Patients with unilateral disease

结局指标

主要结局

Symptom severity total symptoms

时间窗: 1 year

Baseline and change in VAS (visual analogue scale) total nasal, sinus, lung symptoms; 0 (Not at all bothersome) - 100 (Extremely bothersome) mm

次要结局

  • Symptom severity - facial pain(1 year)
  • Symptom severity - wheeze(1 year)
  • Blood eosinophil counts(1 year)
  • Symptom severity - itchy eyes(1 year)
  • Medication use(Registration at time of new prescription and intakes)
  • Symptom severity - post-nasal drip(1 year)
  • Symptom severity - chest tightness(1 year)
  • Symptom severity - impaired smell(1 year)
  • Symptom severity - nasal secretions(1 year)
  • Symptom severity - dyspnoea(1 year)
  • Symptom severity - sneeze(1 year)
  • General health-related quality of life(1 year)
  • CRS-specific quality of life(1 year)
  • Symptom severity - nasal blockage(1 year)
  • Symptom severity - cough(1 year)
  • Disease impact - daily life activities(1 year)
  • Healthcare utilisation(Registration at time of event)
  • Nasal Polyp Score(1 year)
  • Lund-Mackay score(1 year)
  • Hospitalisations(1 year)
  • Symptom severity - itchy nose(1 year)
  • Disease impact - work or school(1 year)
  • Disease impact - sleep quality(1 year)
  • Serum total IgE(1 year)
  • Work Performance and Activity Impairment(1 year)
  • Oral corticosteroid use(1 year)

研究者

发起方
Change Accelerator in Respiratory Care
申办方类型
Industry
责任方
Sponsor

研究点 (13)

Loading locations...

相似试验